11/9
04:15 pm
amrn
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Low
Report
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
11/3
08:30 am
amrn
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
Medium
Report
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
11/1
01:04 am
amrn
Medium
Report
10/29
07:00 am
amrn
Amarin Reports Third Quarter 2025 Financial Results
Medium
Report
Amarin Reports Third Quarter 2025 Financial Results
10/27
08:00 am
amrn
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Medium
Report
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
10/22
06:56 am
amrn
Amarin (NASDAQ:AMRN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Amarin (NASDAQ:AMRN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/15
08:00 am
amrn
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
Low
Report
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
10/14
09:03 am
amrn
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Globe and Mail, The (Toronto, Canada)]
Low
Report
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Globe and Mail, The (Toronto, Canada)]
10/14
09:00 am
amrn
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Yahoo! Finance]
Low
Report
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Yahoo! Finance]
10/14
08:39 am
amrn
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Yahoo! Finance]
Low
Report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Yahoo! Finance]
10/14
08:00 am
amrn
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Low
Report
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
10/6
11:50 am
amrn
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains? [Yahoo! Finance]